# Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies

Source: https://onco.cc/trials/nct07610941/  
OnCo record `nct07610941` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of MST-0312 run by Mestag Therapeutics Limited, now recruiting.

## Summary

Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies is a phase 1 interventional study registered as NCT07610941 by Mestag Therapeutics Limited, with 157 participants planned, started 2026-04-09. Conditions recorded: Cancer-Neoplasms. Interventions recorded: MST-0312 and Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07610941
- Phase: 1
- Setting: A Multi-arm, Open-label, Phase 1 Trial to Evaluate the Safety and Tolerability, Pharmacokinetics and Anti-tumour Activity of MST-0312 When Given Alone and in Combination With Anticancer Treatments in Subjects With Solid Malignancies
- Sponsor: Mestag Therapeutics Limited
- Enrolled: 157

## Sources

- ClinicalTrials.gov NCT07610941: https://clinicaltrials.gov/study/NCT07610941

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [MST-0312](https://onco.cc/drugs/mst-0312/)
- companies: [Mestag Therapeutics](https://onco.cc/companies/mestag-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07610941.json